In this report, we cover catalysts from 28 drugs, devices, diagnostics, and deals expected to occur in early 2022. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. These data points were provided using a combination of Pharmapremia, Informa’s drug development benchmarking product utilizing Biomedtracker’s LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker. The results of the catalysts highlighted in our Q4 2021 Outlook Report can be found on Page 6. At the end of this report, we have included a list of Large Impact catalysts through early 2022.

For the full report, please download the PDF version at the top of the page. Additionally, the catalyst list is provided in Excel by downloading the supplemental material at the top of the page.

For more information on Meddevicetracker, visit its website www.meddevicetracker.com.

Like our report? Have any questions or feedback? Please let us know at askanalyst@sagientresearch.com.

For our disclosures, please read the Biomedtracker Research Standards.